INTRODUCTION
• Neuropathies, characterised by damage to peripheral nerve fibres, are a common long-term complication of diabetes. 1 -Painful diabetic neuropathy occurs in 10% to 20% of patients with diabetes. 2, 3 -Symptoms adversely affect health-related quality of life, 4 and can cause sleep problems, anxiety and depression. 5 • Painful diabetic peripheral neuropathy (PDPN) is a challenging condition to treat.
-Evidence-based treatment guidelines recommend oral agents, including anticonvulsants, tricyclic antidepressants and serotonin noradrenaline reuptake inhibitors. 3, [6] [7] [8] -Localised and topical treatments are also recognised options, 3, [6] [7] [8] including the capsaicin 8% patch (QUTENZA TM ) that has been shown to elicit pain relief in non-diabetic patients with peripheral neuropathic pain. [9] [10] [11] [12] -Two phase III randomised controlled trials (RCTs), STEP 13 and PACE, 14 that evaluated the capsaicin 8% patch in patients with PDPN have recently been completed, leading to an European label extension for the use in adult diabetic patients with peripheral neuropathic pain, either alone or in combination with other pain medications. 15 -Currently, there is no direct clinical evidence comparing the capsaicin 8% patch to oral agents in patients with PDPN.
OBJECTIVES
• A network meta-analysis (NMA) was performed to compare the relative efficacy and tolerability of the capsaicin 8% patch with oral agents recommended by the National Institute for Health and Care Excellence (NICE) for patients with neuropathic pain. 6 
METHODS

Systematic literature review
• A systematic literature review was performed to identify RCTs (published in English after 1950) of pregabalin, gabapentin, duloxetine and amitriptyline in adult patients with PDPN, which were ≥4 weeks in duration.
-Embase/MedLine, Cochrane Library and the National Health Service Centre for Review and Dissemination Database of Abstracts of Reviews of Effects were searched February 2014.
• Data extraction was performed by one reviewer. Extracted data included details of publication, study design, treatment, patient baseline characteristics, patient disposition, and efficacy and tolerability outcomes.
Network meta-analysis
• The impact of treatment effect modifiers (i.e. trial duration, number of participants, baseline pain score, treatment dosing, and the degree of enriched enrolment) on outcomes was assessed to ensure a homogeneous set of studies.
• A Bayesian analytical approach was applied to the NMA to obtain estimates of the relative efficacy and tolerability of the capsaicin 8% patch compared with the four oral agents of interest.
-Both fixed-effects and random-effects models were fitted to the data and considered on the basis of model fit. -The ranking probability of being the best treatment was estimated for each outcome.
• Efficacy outcomes were ≥30% and ≥50% pain reduction from baseline between Weeks 4 to 15, and tolerability outcomes were adverse events commonly associated with the oral comparators (i.e. somnolence, dizziness, nausea, diarrhoea), and the rate of discontinuation due to adverse events.
-Relative effects of treatments were presented as logarithmic odds ratios (OR) with 95% confidence intervals (CI). Forest plots were produced for all outcomes.
• Scenario analyses, which considered different doses (pregabalin, duloxetine), endpoint definitions and inclusion of the open-label PACE trial data, were also performed.
RESULTS
Systematic literature review
• The systematic literature search yielded 400 articles after removing duplicates, of which 51 full text publications were reviewed for eligibility; 24 publications met the inclusion criteria and were fully extracted.
Network meta-analysis
• In addition to the 24 studies identified from the literature review, the NMA also included the STEP trial, which had not been published at the time of the literature search.
-Patients in the STEP trial were allowed to receive concomitant medications, including anticonvulsants, which would have influenced the NMA findings. Therefore, only data from the subpopulation in both arms who did not receive any relevant concomitant oral medications (i.e. pregabalin, gabapentin or duloxetine) at baseline (n=195) were included in the NMA.
• The PACE trial was not included in the base-case NMA as it was an open-label study with safety related primary endpoints.
Heterogeneity assessment
• Relative treatment effect decreased in trials of longer duration (12 to 15 weeks) compared with those of shorter duration (4 to 8 weeks) for efficacy outcomes. Eight trials of <8 weeks treatment duration were excluded from the NMA of efficacy outcomes, aligned with other Cochrane and NICE reviews. [16] [17] [18] [19] • Two trials of amitriptyline, which only reported discontinuation due to adverse events, were excluded because they had markedly lower baseline pain scores to other trials.
Efficacy outcomes
• As goodness of fit was slightly better for the fixed-effects models for all outcomes, data for fixed effects models only are presented.
• The NMA results for both efficacy outcomes are shown in Figure 1 .
-9 and 11 studies were included in the base-case analyses for ≥30% and ≥50% pain reduction, respectively, based on data availability.
• The capsaicin 8% patch was significantly more likely to achieve ≥30% pain reduction than placebo (OR 2.28, 95% CI 1.19-4.03), and showed a trend towards better efficacy compared with placebo for ≥50% pain reduction (OR 1.77, 95% CI 0.84-3.37).
• No statistically significant differences between the capsaicin 8% patch and oral comparators were reported for either of the efficacy outcomes (Figure 1 ).
• The capsaicin 8% patch ranked the second best treatment after duloxetine for ≥30% pain reduction, and the third best treatment after duloxetine and gabapentin for ≥50% pain reduction ( Figure 2 ).
• Scenario analyses (described in Methods) did not significantly change the results (data not shown).
Tolerability outcomes
• The NMA results for tolerability outcomes are shown in Figure 3 .
-The base-case analyses for somnolence, dizziness, nausea, diarrhoea and discontinuation due to adverse events included 18, 18, 12, 10 and 19 trials, respectively, based on data availability. -The capsaicin 8% patch was excluded from the NMA for tolerability as the incidence of these events with the capsaicin 8% patch in the STEP trial was 0%.
• Pregabalin, gabapentin and duloxetine were associated with a significantly elevated risk of somnolence, dizziness and risk of discontinuation due to adverse events compared to placebo, and duloxetine had a significantly higher risk of nausea and diarrhoea than placebo (Figure 3 ).
• Duloxetine had a significantly lower risk of dizziness compared to pregabalin and gabapentin, but duloxetine had a significantly higher risk of nausea compared to pregabalin and gabapentin (Figure 3 ).
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